Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient.
B KhanLianne G SingerL B LillyC ChaparroT MartinuS JuvetM PipkinT K WaddellS KeshavjeeA HumarM CypelPublished in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2017)
Lung transplantation using RNA+ hepatitis C (HCV+) donors to seronegative recipients is not currently performed due to the very high risk of transmission. Previous reports have shown poor survival when this practice was applied. The emergence of new direct-acting antiviral drugs (DAA) suggests a high chance of sustained virologic response in immunocompetent patients. We report here successful transplantation of lungs from HCV+ donor to HCV- recipient. The recipient was an HCV- patient with chronic lung allograft dysfunction. Viral transmission occurred early posttransplant but excellent clinical outcomes were observed including elimination of HCV after 12 weeks of treatment using DAAs.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- end stage renal disease
- newly diagnosed
- ejection fraction
- extracorporeal membrane oxygenation
- healthcare
- primary care
- kidney transplantation
- chronic kidney disease
- stem cells
- peritoneal dialysis
- antiretroviral therapy
- hiv infected
- emergency department
- cell therapy
- replacement therapy
- smoking cessation
- nucleic acid